Pediatride Hiperparatiroidizm

Yıl 2007, Cilt: 5 Sayı: 3, 114 - 117, 01.12.2007

Özgür Pirgon Mehmet Emre Atabek

Öz

Paratiroid hormon; kalsiyum ve fosfor dengesinde kemik, gastrointestinal sistem ve böbrekler üzerinde etkisiyle temel roloynamaktadır. Patolojik durumlarda paratiroid hormonun aflırı artıflı kemik sağlığı üzerinde olumsuz etkiler göstermektedir.Paratiroid hormonun birçok etkisinin anlaflılması iskelette anabolik ajan olarak tedavide kullanılmasına imkan sağlamıfltır.Bu derlemede paratiroid hormonun sekresyonu ve etkisi özetlenmekte ve çocuklarda nadiren görülen hiperparatiroidizm tartışılmaktadır

Anahtar Kelimeler

Paratiroid hormon, çocuk, kemik, hiperparatiroidizm

Hyperparathyroidism in Pediatrics

Öz

Parathyroid hormone plays a vital role in the maintenance of calcium and phosphorus homeostasis through its complexinterplay between the kidney, the gastrointestinal tract, and bone. Under pathologic circumstances, parathyroid hormoneexcess exerts a deleterious effect on skeletal health. Recent enhanced understanding of the manifold actions of parathyroid hormone has allowed its therapeutic application as a skeletal anabolic agent. This review summarizes the basic physiology regulating parathyroid hormone secretion and describes the pathologic conditions associated with parathyroid hormone excess in children

Anahtar Kelimeler

Parathyroid hormone, children, bone, hyperparathyroidism

Kaynakça

• 1. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56:572-81.
• 2. Grant F, Conlin P, Brown E. Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J Clin Endocrinol Metab 1990; 71:370-8.
• 3. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Larsen PR, Kronenberg HM, Melmad S, Polonsky KS, editors. Williams Textbook of Endocrinology. Philadelphia, PA: Saunders; 2003. pp. 1303-71.
• 4. Pearce SHS, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996; 335:1115-22.
• 5. Whyte MP. The long and the short of bone therapy. N Engl J Med 2006; 354:860-3.
• 6. Kronenberg HM. Parathyroid hormone: Mechanism of action. In: Favus MJ, editor. Primer on the metabolic bone dieases and disorders of mineral metabolism. Vol. 2nd edition. Lippincott-Raven Publishers: Philadelphia; 1993.
• 7. Cronin CS, Reeve TS, Robinson B, Clifton-Bligh P, Guinea A, Delbridge L. Primary hyperparathyroidism in childhood and adolescence. J Paediatr Child Health 1996; 32:397-9.
• 8. Harman CR, van Heerden JA, Farley DR, Grant CS, Thompson GB, Curlee K. Sporadic primary hyperparathyroidism in young patients: a separate disease entity? Arch Surg 1999; 134:651-65.
• 9. Monneuse O, Causeret S, Lifante JC, Berger N, Lapras V, Peix JL. Primary juvenile hyperparathyroidism: report of 24 cases. Ann Chir 2002; 127:276-80.
• 10. Fuleihan GE-H. Clinical manifestations of primary hyperparathyroidism. In: Rose BD, editor. UptoDate. Mass: Waltham; 2006.
• 11. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetinum-99m-sestamibi. J Nucl Med 1992; 33:1801-7.
• 12. Atabek ME, Pirgon O, Sert A, Esen HH. Extensive brown tumors caused by parathyroid adenoma in an adolescent patient. Eur J Pediatr. 2007;2:1-5.
• 13. Bilezikian JP, Potts JJ. Asymptomatic primary hyperparathyroidism: new issues and new questions-bridging the past with the future. J Bone Miner Res 2002; 17:57-67.
• 14. Potts JJE. Proceedings of the NIH Consensus Development Conference on Diagnosis and Management of Asymptomatic Primary Hyperparathyrodism. J Bone Miner Res 1991; 6:9-13.
• 15. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10 year prospective study of primary hyperparathyrodism with or without parathyroid surgery. New Engl J Med 1999; 341:1249-55.
• 16. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135-41.
• 17. Reichel H. Current treatment options in secondary renal hyperparathyroidism. Nephrol Dial Transplant 2006; 21:23-8.
• 18. Holick M. High prevalence of vitamin D inadequacy and implications for skeletal health. Mayo Clin Proc 2006; 81:353-73.
• 19. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516-25.